These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 7308336)
41. New World tegumentar leishmaniasis: chemotherapeutic activity of rifampicin in humans and experimental murine model. Do Valle TZ; Oliveira Neto MP; Schubach A; Lagrange PH; Da Costa SC Pathol Biol (Paris); 1995 Sep; 43(7):618-21. PubMed ID: 8570267 [TBL] [Abstract][Full Text] [Related]
42. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710 [TBL] [Abstract][Full Text] [Related]
43. [Meningococcal project Telemark. Experiences after 5 years with contact tracing and eradication of the pathogenic bacteria in near contacts of the patients with meningococcal disease]. Kristiansen BE; Tveten Y; Ask E; Knapskog AB; Reiten T; Steen-Johnsen J; Hopen G Tidsskr Nor Laegeforen; 1993 Sep; 113(23):2933-7. PubMed ID: 8236200 [TBL] [Abstract][Full Text] [Related]
44. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. Motaouakkil S; Charra B; Hachimi A; Nejmi H; Benslama A; Elmdaghri N; Belabbes H; Benbachir M J Infect; 2006 Oct; 53(4):274-8. PubMed ID: 16442632 [TBL] [Abstract][Full Text] [Related]
45. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules. Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530 [TBL] [Abstract][Full Text] [Related]
46. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398 [TBL] [Abstract][Full Text] [Related]
47. [On the use of rifampicin in ophthalmology]. Gaipa M; Inserra E; Diaz F; Striano L Minerva Oftalmol; 1970; 12(6):176-80. PubMed ID: 5524040 [No Abstract] [Full Text] [Related]
48. Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saltoglu N; Tasova Y; Inal AS; Seki T; Aksu HS Saudi Med J; 2002 Aug; 23(8):921-4. PubMed ID: 12235463 [TBL] [Abstract][Full Text] [Related]
49. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey. Sanders M; Van Deun A; Ntakirutimana D; Masabo JP; Rukundo J; Rigouts L; Fissette K; Portaelst F Int J Tuberc Lung Dis; 2006 Feb; 10(2):178-83. PubMed ID: 16499257 [TBL] [Abstract][Full Text] [Related]
50. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560 [TBL] [Abstract][Full Text] [Related]
51. [Use and activity of rifomycin in local treatment of extrapulmonary tubercular forms]. Zanotelli F Fracastoro; 1965; 58(5):353-61. PubMed ID: 5854786 [No Abstract] [Full Text] [Related]
52. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943 [TBL] [Abstract][Full Text] [Related]
53. [Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection]. Sánchez C; Matamala A; Salavert M; Cuchí E; Pons M; Anglés F; Garau J Enferm Infecc Microbiol Clin; 1997 Jan; 15(1):10-3. PubMed ID: 9147500 [TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531 [TBL] [Abstract][Full Text] [Related]
55. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Haley CA; Stephan S; Vossel LF; Sherfy EA; Laserson KF; Kainer MA Int J Tuberc Lung Dis; 2008 Feb; 12(2):160-7. PubMed ID: 18230248 [TBL] [Abstract][Full Text] [Related]
56. [Treatment of newly diagnosed patients with infiltrative and disseminated pulmonary tuberculosis]. Ursov IG; Krasnov VA; B1tashova VA; Kudelia OA; Volkova ZhA; Gromyko NI; Borovinskaia TA Probl Tuberk; 1998; (4):21-2. PubMed ID: 9771031 [TBL] [Abstract][Full Text] [Related]